The most common safety concerns for SGLT-2 inhibitors were the risk of renal dysfunction (50.4%, n=126), diabetic ketoacidosis (37.6%, n=94), and urinary tract infections (28%, n=70). The gene discussed is SLC5A2; the disease is urinary tract infection.